MedTrace Logo

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer

NCT00299390 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-12-31

No results posted yet for this study

Summary

The purpose of this study is to determine whether the study drug is effective and safe in the first line treatment of patients with small cell lung cancer

Conditions

  • Small Cell Lung Carcinoma

Interventions

DRUG

Sagopilone (BAY86-5302, ZK 219477)

Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-04-30
Completion
2007-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00299390 on ClinicalTrials.gov